Differential survival and recurrence patterns of patients operated for breast cancer according to the new immunohistochemical classification: analytical survey from 1997 to 2012

Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. A single institution survey spanning 1998 to 2010

(2012) A. García Fernández et al.   BREAST

Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: Long-term follow up on IBCSG Trial IX

(2011) S. Aebi et al.   ANNALS OF ONCOLOGY

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

(2011) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Triple negative breast cancer: Proposals for a pragmatic definition and implications for patient management and trial design

(2011) W. Eiermann et al.   BREAST

High estrogen receptor expression in early breast cancer: chemotherapy needed to improve RFS?

(2011) A. C. Regierer et al.   BREAST CANCER RESEARCH AND TREATMENT

Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer

(2011) L. C. Collins et al.   BREAST CANCER RESEARCH AND TREATMENT

Body Size, Physical Activity, and Risk of Triple-Negative and Estrogen Receptor-Positive Breast Cancer

(2011) A. I. Phipps et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: A retrospective clinical study

(2011) P. Sanpaolo et al.   EJSO

A comparison of international breast cancer guidelines – Do the national guidelines differ in treatment recommendations?

(2011) R. Wolters et al.   EUROPEAN JOURNAL OF CANCER

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

(2010) M. Elizabeth H. Hammond et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of Axillary Ultrasound, Ultrasound-Fine Needle Aspiration Biopsy and Magnetic Resonance Imaging in the Preoperative Triage of Breast Cancer Patients Considered for Sentinel Node Biopsy

(2010) Antonio García Fernández et al.   ULTRASOUND IN MEDICINE AND BIOLOGY

Breast Cancer Subtypes as Defined by the Estrogen Receptor (ER), Progesterone Receptor (PR), and the Human Epidermal Growth Factor Receptor 2 (HER2) among Women with Invasive Breast Cancer in California, 1999-2004

(2009) Carol A. Parise et al.   Breast Journal

High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2–Positive, Node-Negative Tumors 1 cm or Smaller

(2009) Ana M. Gonzalez-Angulo et al.   JOURNAL OF CLINICAL ONCOLOGY

Gene-Expression Signatures in Breast Cancer

(2009) Christos Sotiriou et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer

(2008) James J. Dignam et al.   BREAST CANCER RESEARCH AND TREATMENT

The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: The California Cancer Registry, 1999–2004

(2008) Monica Brown et al.   CANCER

Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

(2008) M. C.U. Cheang et al.   CLINICAL CANCER RESEARCH

Breast Cancer Subtype Approximated by Estrogen Receptor, Progesterone Receptor, and HER-2 Is Associated With Local and Distant Recurrence After Breast-Conserving Therapy

(2008) Paul L. Nguyen et al.   JOURNAL OF CLINICAL ONCOLOGY